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Nucleobase-modiﬁed antisense oligonucleotides
containing 5-(phenyltriazol)-20-deoxyuridine
nucleotides induce exon-skipping in vitro†
Bao T. Le,ab Mick Hornum, c Pawan K. Sharma,d Poul Nielsen c
and Rakesh N. Veedu *ab
Chemically-modiﬁed antisense oligonucleotide-mediated exon-skipping has been validated as
a therapeutic strategy for tackling several disease pathologies, particularly duchenne muscular dystrophy.
To date, only sugar-modiﬁed and internucleotide linkage-modiﬁed oligonucleotide chemistries have
been explored for exon-skipping applications. Herein, for the ﬁrst time, we have investigated the
potential of nucleobase-modiﬁed antisense oligonucleotides to induce exon-skipping. For this purpose,
we have synthesised 5-(phenyltriazol)-20-deoxyuridine-modiﬁed 20-O-methyl mixmer antisense
oligonucleotides, and evaluated their eﬃcacy to induce exon-23 skipping in H-2Kb-tsA58 (H2K) mdx
mouse myotubes as a model system. Our results showed that the phenyltriazol base-modiﬁed AOs
successfully induced eﬃcient exon-skipping in a DMD transcript. Our ﬁndings open up the exploration
of novel base-modiﬁed antisense oligonucleotides for exon-skipping applications.
Introduction
Antisense oligonucleotide (AO)-based therapy has now been
established as one of the most promising approaches for the
treatment of various diseases. The use of chemically-modied
nucleotides is paramount to improve the pharmacokinetics of
AO-based therapeutic molecules. Last year, two AO drug
candidates, Exondys 51 for the treatment of duchennemuscular
dystrophy (DMD) and nusinersen for the treatment of spinal
muscular atrophy (SMA), have been approved by the US Food
and Drug Administration (FDA), bringing the total number of
FDA approved antisense oligonucleotide drugs to four.1,2 With
the approval of Exondys 51 for the treatment of DMD, AO-
mediated splice modulation has now emerged and been vali-
dated as a viable treatment alternative. DMD is a serious X-
linked muscle wasting genetic disorder.3,4 Patients with DMD
lack dystrophin protein due to mutations in one or more exons
of the dystrophin gene required for muscle contraction and
protection. Exondys 51 is a 30-nucleotide long phosphor-
odiamidate morpholino oligomer (PMO) AO targeting exon-51
in the dystrophin gene transcript. In addition, another AO
drug candidate drisapersen composed of 20-O-methyl (20-O-Me)
nucleotides on a phosphorothioate (PS) backbone entered
phase-3 clinical trials, and was later rejected by the FDA based
on poor eﬃcacy and toxicity issues.
So far, several antisense oligonucleotide chemistries have
been explored for their potential to modulate splicing or induce
exon-skipping.5–16 However, only sugar moiety and phosphate
backbone modied-AOs have been investigated for exon-
skipping applications. We envisioned the scope of
nucleobase-modied AOs to induce exon-skipping. Towards
this, Nielsen and colleagues reported the synthesis of 5-(phe-
nyltriazol)-20-deoxyuridines that showed improved duplex
stability when targeting a complementary RNA.17–20 Improved
duplex stability upon incorporation of 5-(phenyltriazol)-20-
deoxyuridine nucleotides is believed to be due to the p–p
stacking of the aromatic substituents. Herein, we describe for
the rst time that the design and synthesis of 5-(phenyltriazol)-
20-deoxyuridine/20-O-Me (Fig. 1) mixmer RNA AOs and evaluate
its eﬃcacy to induce exon-skipping in vitro in H-2Kb-tsA58 (H2K)
mdx myotubes.
Experimental
Design and synthesis of antisense oligonucleotides used in
this study
All AOs (Table 1) were prepared in-house on an AKTA Oligopilot
synthesizer (GE Healthcare Life Sciences) via standard phos-
phoramidite chemistry in 1 mmol scale. Synthesized oligonu-
cleotides were deprotected and cleaved from the solid support
by treatment with NH4OH at 55 C overnight. The crude
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oligonucleotides were then puried, desalted and veried by
HPLC and MALDI-ToF MS analysis (see ESI† for detailed
procedure and analysed data).
Melting temperature analysis of the antisense
oligonucleotides
Three antisense oligonucleotides: control 20-O-MePS, ON1 and
ON2 were prepared at 2 mM concentrations in a buﬀer solution
containing 10 mM NaCl, 0.01 mM EDTA adjusted to pH 7.0 by
10 mM sodium phosphate buﬀer. The AOs were then mixed
with the synthetic complementary RNA sequence (2 mM) at
equal volume and denatured at 95 C for 10 minutes followed by
cooling down to room temperature and loaded onto a quartz
cuvette of 1 mm path-length. The melting process was moni-
tored by Shimadzu UV-1800 with the temperature controller
over the range of 20–90 C at a ramp rate of 1.0 C min1. Tm
values were then calculated by the rst derivative.
Cell culture and transfection
H-2Kb-tsA58 (H2K) mdx mouse myoblast (provided by Prof. Sue
Fletcher and Prof. Steve Wilton's laboratory, Murdoch Univer-
sity, Australia) were cultured as described previously.21,22 Briey,
when 60–80% conuent, primary mdx myoblast cultures were
treated with trypsin (Life Technologies) and seeded at a density
of 2  104 cells per well into 24 well plates. The plates were pre-
treated with 50 mg ml1 poly-D-lysine (Sigma) and 100 mg ml1
Matrigel (Corning). Cultures were then allowed to diﬀerentiate
into myotubes in Dulbecco's Modied Eagle Medium (DMEM)
containing 5% horse serum by incubating at 37 C, 5% CO2 for
24 hours. Antisense oligonucleotides were complexed with
Lipofectin (Life Technologies) at the ratio of 2 : 1 (Lip-
ofectin : AO) and used in a nal transfection volume of 500 ml
per well in a 24-well plate as per the manufacturer's instruc-
tions, except that the solution was not removed aer 3 hours.
RNA extraction and reverse transcription-polymerase chain
reaction (RT-PCR)
RNA was extracted from transfected cells using Direct-zol™
RNA MiniPrep Plus with TRI Reagent® (Zymo Research) as per
the manufacturer's instructions. The dystrophin transcripts
were then analysed by nested RT-PCR across exons 20–26 as
described previously.22,23 PCR products were separated on 2%
agarose gels in Tris–acetate–EDTA buﬀer and the images were
captured on a Fusion Fx gel documentation system (Vilber
Lourmat, Marne-la-Vallee, France). Densitometry analyses was
performed by Image J soware.24 To quantify the actual exon-
skipping eﬃciency, the amount of exon-23 skipped RT-PCR
product is expressed as a percentage of total dystrophin tran-
script products.
Cell viability assay
Cells were seeded and transfected with the AOs at 50 and
200 nM as described previously. Aer 24 h, cell viability assay
was performed using a colorimetric assay (WST-1, Sigma).
Briey, WST-1 solution was added at ratio 1 : 10 (v/v) per well
and incubated for 4 h at 37 C, 5% CO2. The absorbance was
then measured with a microplate reader (FLUOstar Omega,
BMG Labtech, Germany) at 450 nm.
Results and discussion
First, we designed and synthesised two 20-mer 20-O-MePS AOs
containing 5-(phenyltriazol)-20-deoxyuridine nucleotides in
parallel to a previously reported 20-O-Me phosphorothioate (PS)
AO.22,23 The rst AO sequence (ON1) contained two 5-(phenyl-
triazol)-20-deoxyuridine nucleotides at positions 10 and 16, and
the second AO (ON2) had two consecutive 5-(phenyltriazol)-20-
deoxyuridine nucleotides at positions 15 and 16 respectively
(Table 1). To assess the binding aﬃnity of the modied AOs
against its RNA target, we initially performed the thermal
stability analysis using a synthetic complementary RNA
sequence (Table 1) in parallel to the control 20-mer 20-O-MePS
AO. In line with previous reports,17–20 ON1 containing two 5-
(phenyltriazol)-20-deoxyuridine nucleotides positioned ve
nucleotides apart from each other showed slight destabilization
of the heteroduplex with lower Tm of 58.8 C compared to the
20-mer 20-O-MePS control AO sequence (62.9 C). On the other
hand, the AO sequence containing two consecutive 5-(phenyl-
triazol)-20-deoxyuridine nucleotides showed similar Tm (62.8 C)
to the unmodied control 20-O-MePS AO sequence, probably
due to stronger p–p stacking interaction (Table 1).
Fig. 1 Structural presentation of the nucleic acid analogues used in
this study.
Table 1 AO names and sequences used in this studya
AOs names Sequence, 50/ 30 direction Tm (C)
20-O-MePS GGCCAAACCUCGGCUUACCU 62.9
ON1 GGCCAAACCUCGGCUUACCU 58.8
ON2 GGCCAAACCUCGGCUU ACCU 62.8
a Complementary synthetic RNA target: 50-r(AG GUA AGC CGA GGU
UUG GCC)-30. 5-(Phenyltriazol)-20-deoxyuridine monomers are
represented in bold underlined letters. Melting temperature curves
are shown in Fig. S1 (ESI).
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 54542–54545 | 54543
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We then evaluated the exon-skipping eﬃciency of the AOs in
vitro using H-2Kb-tsA58 (H2K) mdx mouse myotubes. Briey,
H2K mdx myoblasts were plated for diﬀerentiation into myo-
tubes 24 h prior to transfection with the AOs using lipid-based
delivery agent Lipofectin (2 : 1 ratio of lipo : AO) at 25, 50, 100
and 200 nM. The cells were then collected aer 24 h of treat-
ment and the RNA was extracted followed by reverse-
transcriptase polymerase chain amplication (RT-PCR) anal-
ysis by amplifying the product across exon 20–26 as previously
reported.22,23 The results clearly demonstrated that all three AOs
eﬃciently induced exon-23 skipping in DMD transcript at all
concentrations from 25 nM to 200 nM (Fig. 2A) in a dose-
dependent manner by yielding the skipped product of 688 bp
from the full-length 901 bp product. The actual exon-skipping
eﬃciencies of the AOs were analysed by densitometry (semi-
quantitative) and the percentage of exon-23 skipping was
determined by analysing the amount of exon-23 RT-PCR
product over the full-length dystrophin product band. Densi-
tometry results revealed that the ON1 containing two distantly
positioned 5-(phenyltriazol)-20-deoxyuridines achieved slightly
higher exon-23 skipping eﬃciency at 25 nM (57%) and 50 nM
(61%) concentrations compared to the control 20-O-MePS AO
(51% and 60% respectively at 25 and 50 nM) (Fig. 2A and B).
However, at higher concentrations, the full 20-O-MePS AO
showed higher exon-23 skipping eﬃcacy (69% at 100 and 70%
200 nM; Fig. 2A and B). Notably, ON2 containing two consecu-
tive 5-(phenyltriazol)-20-deoxyuridines showed slightly reduced
exon-skipping eﬃcacy at both lower (47 and 54% at 25 and
50 nM, respectively) and higher concentrations (57 and 62% at
100 and 200 nM, respectively; Fig. 2A and B). This observation
does not correlate with the melting temperature analysis data.
We speculate that this may be due to the structural features of
the AO in the cellular environment which may distort the AO-
target complex because of the positioning of the 5-(phenyl-
triazol)-20-deoxyuridine monomers, and this needs to be further
investigated.
We also observed the presence of another weak product band
at 542 bp which is believed to be due to the unfavourable dual
exon-22/23 skipping (Fig. 2A). All three AOs induced the dual
exon-22/23 skipping at all concentrations and the intensity
increases with increasing concentrations, however, the yields
were generally very low in all cases, ranging from 15–28%,
compared to the major expected exon-23 skipped product of 688
bp (51–70%). ON1 induced slightly more dual exon-22/23 skip-
ping compared to other AOs at 100 nM (28%), but the
percentage reduced to 25% at 200 nM, which is comparable to
the control AO (26%) and ON2 (24%) (Fig. 2B).
We then performed the cell viability assay to assess the
toxicity of the base-modied AOs in parallel to 20-O-MePS AO.
Overall, the AOs (20-O-MePS, ON1 and ON2, respectively) were
found to be relatively non-toxic to cells at 50 nM dose with 95, 96
and 98% cell viable compared to the untreated (Fig. 3). In line
with our previous report,6 the 20-O-MePS AO was found to be
slightly toxic at 200 nM with the cell vitality reduced to 84%,
while the nucleobase modiedON1 andON2maintained 93 and
91% of cell viability respectively at 200 nM (Fig. 3). These results
may indicate the benet of incorporating the nucleobase-
modied nucleotides such as 5-(phenyltriazole)-20-deoxyuridine
in reducing the cytotoxic eﬀect of the 20-O-MePS AO.
It is worth mentioning that the 5-(phenyltriazole)-20-deoxy-
uridine building block is a logical choice since it is one of the
nucleobase-modications that has demonstrated the most
positive eﬀects on the thermal duplex stability to date,17 but this
property requires at least two of these modications are placed
consecutively. Not only is this work the rst time this building
block is incorporated along with 20-O-Me in phosphorothioated
oligonucleotides, but it is also the rst time that this building
block is examined in vitro in cells for antisense applications.
Notably, the current work unintuitively demonstrates that the
exon-skipping potential of the oligonucleotides is slightly better
when the 5-(phenyltriazole)-20-deoxyuridine building blocks are
placed distantly compared to consecutively, and that the
melting temperature (i.e. hybridization strength) is therefore
Fig. 2 (A) RT-PCR analysis of exon-23 skipping in H2K mdx mouse
myotubes; (B) densitometry analysis of exon-23 skipping in H2K mdx
mousemyotubes. Concentration range: 25, 50, 100 and 200 nM; gray:
full-length exon 23 product; green: exon-23 skipping product; blue:
dual exon-22/23 skipping product; UT: untreated; ve: negative
control.
Fig. 3 Cell viability assay of the AOs inH2Kmdxmousemyotubes. UT:
untreated.
54544 | RSC Adv., 2017, 7, 54542–54545 This journal is © The Royal Society of Chemistry 2017
RSC Advances Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
9/
12
/2
01
7 
08
:1
9:
49
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
may not be necessarily a good indicator for skipping eﬃciency
in the context of the 5-(phenyltriazol)-20-deoxyuridine building
block. As these are only our preliminary investigation towards
the application of base-modied AOs in exon-skipping, this
nding can help to improvise the AO design in future exon-
skipping experiments containing base-modied nucleotides
with multiple chemistries.
Conclusions
In summary, we have designed and synthesized two 20-O-MePS
mixmer RNA AOs containing two 5-(phenyltriazol)-20-deoxyur-
idine monomers placed at distant positions and consecutively,
and evaluated their potential to induce exon-skipping in DMD
transcript using H2K mdxmouse myotubes. We found that a 20-
O-MePS AO containing two distantly placed 5-(phenyltriazol)-20-
deoxyuridines induced higher exon-23 skipping at low concen-
trations, compared to the previously reported control 20-O-MePS
AO. Contrary to the melting temperature analysis data, the AO
containing two consecutive 5-(phenyltriazol)-20-deoxyuridines
were not as eﬀective, highlighting the impact of the modied
monomer positions. Although we report the rst demonstration
of exon-skipping using nucleobase-modied AOs, further
investigations are necessary to gain more insights about the
positioning and also in combination with other sugar-modied
nucleotides such as locked nucleic acid (LNA) nucleotides.25,26
Our results open the scope of exploring novel base-modied
nucleic acid analogues in combination with other chemistries
for their potential in constructing eﬃcient exon-skipping AOs.
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